Dr. Fadi Braiteh, celebrated for advancing immunotherapy, to highlight the latest treatments in fighting cancer
May 13, 2016 – Monaco Growth Forums by Andreea Porcelli announced today that distinguished Comprehensive Cancer Centers of Nevada (CCCN) oncologist and Clinical Associate Professor of the University of Nevada School of Medicine, Dr. Fadi Braiteh, will serve as the keynote speaker at the forum’s gala on July 26th AT 8:30pm during the Gala Dinner in Monte Carlo.
Dr. Braiteh’s presentation, titled “Immuno-oncology: A Leap Forward to Making Cancer a Curable Disease,” will shed light on how cancer treatment has evolved as well as the most recent innovations in the field of immunotherapy – a method of treatment that empowers the patient’s immune system to combat aberrant, harmful cancerous cells. Dr. Braiteh will join esteemed philanthropists and executives vested in the field of cancer immunotherapy to increase support and awareness of the treatment option.
“It is a transformative time in healthcare and at the heart of many of these exciting headlines and developments is immunotherapy,” said Dr. Braiteh. “I look forward to sharing my unique, firsthand experiences pertaining to this new era in cancer treatment with Monaco Growth Forums attendees and hope my insight can inspire positive action in their everyday lives.”
Dr. Braiteh directs CCCN’s Translational Oncology Program (TOP-Phase 1), in collaboration with the US Oncology Research Network, and leads the development of novel anti-cancer agents, many of which are being used in humans for the very first time.
Among Dr. Braiteh’s numerous clinical trials, he participated in the conduction of immunotherapy compound agents including Nivolumab, Pembrolizumab, Avelumab, Durvalumab, Atezolizumab, Ipilumab as well as others in earlier stage of development. Temilumab is being developed to treat several sub-types of cancer such as lung, triple negative breast, bladder and other hematological malignancies. CCCN was originally one of the first few centers in the U.S. for “first in-human” testing and, in 2014, the Food and Drug Administration (FDA) named it a “breakthrough therapy” in bladder and lung cancers. Dr. Braiteh’s clinical research has been published in peer-reviewed journals such as Nature, Lancet, Lancet Oncology and Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.
About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Based on more than 20 years’ experience as an international Investment Banker finding investors for small cap companies on a world scale, MGF Founder and President Andrea Porcelli and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high net worth individuals, industry-related sponsors and foundations – all selected on an exclusive basis.